If not, another escalation may be appropriate
GLP-1, short for glucagon-like peptide-1, is a hormone released in the gut after eating
Based on Phase 2 trial data (Jastreboff et al., NEJM , 2023), the most commonly reported adverse effects of retatrutide include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (most frequent, particularly during dose escalation) Injection site reactions: Redness, bruising, or mild discomfort Decreased appetite: Generally considered a therapeutic effect but can contribute to nutritional deficiency if severe Increased heart rate: Observed with glucagon receptor agonism
Do you have a hard time living in the grey zone, thinking things are either all bad or all good
This increased cAMP activates PKA which in turn promotes insulin synthesis and secretion and inhibits glucagon release (Yang and Yang, 2016)